Skip to main content
Equibles
NVCT logo

NVCT · Nuvectis Pharma, Inc. · Metrics

Track NVCT — free

Use NVCT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NVCT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$20.89 +0.19 (+0.92%) At close · Oct 22
Russell 2000 member Rebalance outlook locked
Market Cap
$680.63M
Shares
32.58M
Volume · Oct 22 110.06K Avg daily vol (3M) 205.89K

NVCT metrics

60 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$20.89
Market cap
$680.63M

Price action

20 metrics
Price change (1W)
+10.4%
Price change (30D)
-9.2%
Price change (3M)
+3.7%
Price change (6M)
+137.7%
Price change (YTD)
+176.7%
Price change (1Y)
+252.9%
Trailing year
Price change (5Y)
—
52-week high
$28.53
52-week low
$5.65
Change from 52-week high
-26.8%
Change from 52-week low
+269.7%
Annualized volatility
85.7%
Annualized volatility (3M)
70.9%
Beta
0.9
RSI (14D)
52.1
Price vs SMA 50
-3.7%
Price vs SMA 200
+46.0%
Avg volume (3M)
205,894
Relative volume
0.5
Average dollar volume
$4.42M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
32.58M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
74.3
reciprocal yield 1.3%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-4.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-06-22

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$28.87M
Net income (TTM)
−$27.85M
Trailing 12 months
Diluted EPS (TTM)
$-1.31
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.25
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.20
Operating cash flow per diluted share (TTM)
$-0.84
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.85
Stock compensation per diluted share (TTM)
$0.28
Book value per share
$0.72

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+9.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-306.6%
Return on assets
-124.4%
Debt / equity
—
Current ratio
1.7
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$22.16M
Latest balance sheet
Cash & equivalents
$22.16M
Total assets
$22.38M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$19.51M
Capital expenditures (TTM)
—
R&D (TTM)
$19.65M
SG&A (TTM)
—
Stock compensation (TTM)
$6.49M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
84
13F filer change QoQ
+21
Institutional ownership
32.9%
Conviction holders (share of 13F filers)
1.2%
Crowding (high-turnover and private-fund holders)
17.0%
Private-fund adviser ownership
12.8%
Active holders' share change QoQ
+234.9%
Holder tenure
4.6
Price vs estimated holder cost
+80.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
6.1%

Short interest

3 metrics
Short interest
7.7%
Latest settlement · 10.3 days to cover
Days to cover
10.3d
Short-squeeze score
74 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1875558 CUSIP 67080T108 13F (30d) 10 filings 10 filers Visit website Investor relations